Related Experiment Video
Updated: Jul 3, 2026

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
Published on: February 24, 2026
Continuous intrathecal baclofen infusion for intractable spastic cerebral palsy--is it worth it?
1Pediatric Neurology, Shriners Hospitals for Children-Portland, Oregon Health and Science University, Portland, OR 97201, USA. russmanb@ohsu.edu
Insights
Continuous intrathecal baclofen infusion (CIBI) is a cost-effective treatment for children with cerebral palsy, improving quality of life despite higher initial costs. This approach enhances care and comfort for severe spasticity and dystonia.
Area of Science:
- Pediatric Neurology
- Rehabilitation Medicine
- Health Economics
Background:
- Cerebral palsy (CP) management for severe spasticity and dystonia involves multiple interventions.
- Continuous intrathecal baclofen infusion (CIBI) is a key treatment for severe tone impacting function and quality of life in children with CP.
Discussion:
- A study by Hoving et al. evaluated the cost-effectiveness of CIBI versus standard care in pediatric CP.
- CIBI incurs nearly double the annual cost compared to standard care.
- The analysis considered improvements in quality of life to assess value.
Key Insights:
- Despite higher costs, CIBI was found to be cost-effective when quality of life improvements were factored in.
- The study supports previous findings on the long-term value of CIBI in pediatric CP.
- Quality of life gains justify the increased healthcare expenditure for CIBI.
Outlook:
- Further research with larger cohorts and longer follow-up periods could strengthen these findings.
- CIBI represents a valuable therapeutic option for optimizing care and comfort in children with severe CP.
- Economic evaluations are crucial for guiding treatment decisions in managing complex pediatric conditions.
Abstract:
This Practice Point commentary discusses a recent paper by Hoving et al., who compared the cost-effectiveness of continuous intrathecal baclofen infusion (CIBI) with that of 'standard care' in children with cerebral palsy whose abnormal muscle tone was interfering with function and/or quality of life. The current management of severe spasticity and dystonia in cerebral palsy consists of oral medications, botulinum toxin, selective dorsal rhizotomy, orthopedic surgery, and/or CIBI. CIBI is the treatment of choice for patients whose severely abnormal tone is interfering with their care, comfort, and/or quality of life. The added cost of care associated with the use of CIBI for 1 year is nearly twice that of standard care. However, on the basis of their cost-effectiveness analysis, which took into consideration the improvement in quality of life, Hoving et al. concluded that the added expense is cost-effective. Although this prospective study lasted for only 1 year and included only 15 patients, the conclusions are similar to those based on previously published results.
More Related Videos
Related Concept Videos
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Local Anesthetics: Clinical Application as Spinal Anesthesia

